GIGABYTE
15.2.2024 18:31:29 CET | Business Wire | Press release
GIGABYTE Technology, an IT pioneer whose focus is to advance global industries through cloud and AI computing systems, is coming to MWC 2024 with its next-generation servers empowering telcos, cloud service providers, enterprises, and SMBs to swiftly harness the value of 5G and AI. Featured is a cutting-edge AI server boasting AMD Instinct™ MI300X 8-GPU, and a comprehensive AI/HPC server series supporting the latest chip technology from AMD, Intel, and NVIDIA. The showcase will also feature integrated green computing solutions excelling in heat dissipation and energy reduction.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240215917651/en/
Inviting the AI-powered 5G Era, GIGABYTE will Present Next-Gen Servers for AI HPC, Telecom, and Green Computing Solutions at MWC 2024
Continuing the booth theme “Future of COMPUTING”, GIGABYTE's presentation will cover servers for AI/HPC, RAN and Core networks, modular edge platforms, all-in-one green computing solutions, and AI-powered self-driving technology. The exhibits will demonstrate how industries extend AI applications from cloud to edge and terminal devices through 5G connectivity, expanding future opportunities with faster time to market and sustainable operations. The showcase spans from February 26th to 29th at Booth #5F60, Hall 5, Fira Gran Via, Barcelona.
Tomorrow’s AI Supercomputers
The demand for AI-ready infrastructure and high-speed storage is escalating within the 5G framework, business operations, and academic research, driven by the exponential growth in data volume and the complexity of AI models. GIGABYTE will showcase its latest series of AI/HPC servers and an all-flash array (AFA) storage server. These servers support AMD Instinct™ MI300X OAM GPU modules, MI300A APUs, 5th Gen Intel® Xeon® Scalable Processors, NVIDIA HGX H100 8-GPU, and NVIDIA Grace Hopper Superchip, also leveraging the next-gen HBM3, ensuring hyper-speed data transmission. This technological leap is poised to advance exascale AI workloads and real-time big data analysis.
Flexible Server Architectures for the AI-enabled 5G Networks
The massive deployment of 5G applications requires flexibly configured digital infrastructure capable of supporting diverse IT ecosystems. GIGABYTE will introduce one of its modular edge platforms designed to manage a wide range of workloads, including networking, AI inferencing, and cloud computing. This platform offers seamless upgrades to accommodate multi-generational chip technologies and components, ensuring agile adaptation to rapid market changes with minimized maintenance costs.
In response to the rising demand for 5G and AI applications across businesses of varying scales, GIGABYTE will introduce its latest servers tailored for RAN and Core networks. These servers offer robust performance, catering to a range of computing needs from large-scale cloud-native workloads and telecom services to SMB IT operations. They excel in energy efficiency and provide expansion opportunities for AI-accelerated computing.
Sustainable AI and Cloud Computing Ensures Optimized TCO
At MWC, GIGABYTE is set to showcase its comprehensive all-in-one green computing solution, featuring a large-scale immersion cooling tank and two immersion-ready servers tailored for AI and cloud computing. The exhibit emphasizes their remarkable heat-dissipation capabilities and significantly lower power consumption. These features translate into a favorable total cost of ownership (TCO), highlighting GIGABYTE's commitment to sustainable and efficient computing solutions.
Future-Proof E-mobility Driven by Edge AI
Leveraging the 5G network and advanced AI algorithms, GIGABYTE's autonomous vehicle technology offers an exceptionally intelligent driving experience driven by edge AI. The high-speed data transmission performance ensures that GIGABYTE's Advanced Driver Assistance Systems (ADAS) and telematics efficiently process vast amounts of data from cameras, radars, and ultrasonic sensors. This enables the system to deliver precise real-time driving decisions, even in complex road conditions.
At GIGABYTE’s booth, enterprises can explore innovative and flexible computing solutions aligning with their strategies to gain a competitive edge in the AI-accelerated 5G future.
Visit GIGABYTE’s MWC event page.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240215917651/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom